335 related articles for article (PubMed ID: 17472569)
1. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
2. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated silencing of huntingtin expression by shRNA.
Huang B; Kochanek S
Hum Gene Ther; 2005 May; 16(5):618-26. PubMed ID: 15916486
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
5. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
7. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.
Machida Y; Okada T; Kurosawa M; Oyama F; Ozawa K; Nukina N
Biochem Biophys Res Commun; 2006 Apr; 343(1):190-7. PubMed ID: 16530728
[TBL] [Abstract][Full Text] [Related]
8. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
11. Viral-mediated overexpression of mutant huntingtin to model HD in various species.
Ruiz M; Déglon N
Neurobiol Dis; 2012 Nov; 48(2):202-11. PubMed ID: 21889981
[TBL] [Abstract][Full Text] [Related]
12. Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference.
Chen ZJ; Kren BT; Wong PY; Low WC; Steer CJ
Biochem Biophys Res Commun; 2005 Apr; 329(2):646-52. PubMed ID: 15737634
[TBL] [Abstract][Full Text] [Related]
13. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
15. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
Garriga-Canut M; Agustín-Pavón C; Herrmann F; Sánchez A; Dierssen M; Fillat C; Isalan M
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3136-45. PubMed ID: 23054839
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
[TBL] [Abstract][Full Text] [Related]
17. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
Harper SQ; Staber PD; He X; Eliason SL; Martins IH; Mao Q; Yang L; Kotin RM; Paulson HL; Davidson BL
Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5820-5. PubMed ID: 15811941
[TBL] [Abstract][Full Text] [Related]
18. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
19. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
20. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
